US deal for 100 million doses of vaccine

US deal for 100 million doses of vaccine

Sanofi and GSK's drug is a so-called recombinant protein-based vaccine, which means that it involves using DNA to encode an antigen, toxin or other foreign substance, which induces an immune response in the vaccinated person. "From everything we've seen now - in the animal data, as well as the human data - we feel cautiously optimistic that we will have a vaccine by the end of this year and as we go into 2021", he said.

Sanofi, which will receive the bulk of the USA funding, developed the vaccine candidate. "Today's investment supports our latest vaccine candidate, an adjuvanted product being developed by Sanofi and GSK, all the way through clinical trials and manufacturing, with the potential to bring hundreds of millions of safe and effective doses to the American people".

"From the beginning of the pandemic, Sanofi has leveraged its deep scientific expertise and resources to help address this crisis, collaborating with the US Department of Health and Human Services to unlock a rapid path toward developing a pandemic vaccine and manufacturing at large scale".

Dr. Moncef Slaoui, a former GSK executive, is head of the White House's Operation Warp Speed, the administration's program to develop and disburse an effective coronavirus vaccine.

The federal government would own the doses of the vaccine, which could be used in clinical trials or be distributed if it gets authorization from the Food and Drug Administration.

Manchester City close to snapping up star winger Ferran Torres
Manchester City have included hard to achieve performance-based add-ons in an agreement with Valencia for Ferran Torres . Despite Bournemouth's relegation to the Championship , Ake's reputation has soared since he left Chelsea in 2017.

"The portfolio of vaccines being assembled for Operation Warp Speed increases the odds that we will have at least one safe, effective vaccine as soon as the end of this year", HHS Secretary Alex Azar said in a written statement announcing the deal. "Those who were administered the vaccine have been kept under observation and all of them are absolutely fine", he said. "We look forward to this trial demonstrating the potential of our vaccine to prevent COVID-19, so that we can defeat this pandemic".

The European Commission, armed with an emergency fund of €2 billion ($2.4 billion), wants to strike similar deals with up to six pharmaceutical companies in a bid to procure vaccines for its 450 million citizens.

The companies said the doses would be manufactured in European countries including France, Belgium, Germany and Italy.

Last week, American multinational pharmaceutical company Pfizer and German biotechnology firm BioNTech announced that they had struck a $1.95 billion deal with the United States federal government to produce 100 million doses of their COVID-19 vaccine, which is now in phase three trials. ACT partners include leaders of governments, global health organizations, businesses and philanthropies.

Related Articles